We are a biobank and tissue engineering biotech focusing on the umbilical cord to improve biobanking service and therapies to virtually any human tissue degeneration. The umbilical cord contains at least 8 quality products (including cells, stem cells, extracellular matrix, plasma, platelets and exosomes) necessary to build virtually any human tissue. Yet, 90% of cords are treated as biological waste and the rest is minimally used for 1 inefficient regenerative medicine product or for a relatively small number of rare conditions like leukemia. We are making every umbilical cord indispensable to families and revolutionizing regenerative medicine. We are a novel patented private and public biobank. SCR is the only biobank and biotech with significant IP to build better human tissues from better cellular and extracellular products all derived from each umbilical cord. Partnering with expectant families, industry and medical professionals. Please reach out to investor relations at [email protected]
There is no investment information
No recent news or press coverage available for Stem Cell RESERVE.